← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Dekk-Tec, Inc.
New Orleans, LA
$7,374,808
Total funding
13
Grants
Funding over time
peak $805.5K · FY2005–20$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$7,374,808 · 13
By mechanism
R44$6,048,786 · 7
R43$1,326,022 · 6
Investigators at Dekk-Tec, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
A-007: Immune Modulation of HPV - Associated Neoplasia$805,491
R44 · FY2005 · CA
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN): A Phase II Clinica$638,567
R44 · FY2013 · CA
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN): A Phase II Clinica$522,886
R44 · FY2014 · CA
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN: A Phase II Clinical Trial in Adolescents/Young Adults (AYA)with CNS Malignancies$519,480
R44 · FY2019 · CA
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN: A Phase II Clinical Trial in Adolescents/Young Adults (AYA)with CNS Malignancies$451,382
R44 · FY2020 · CA
Camptothecin Analogs for Cancer Therapy$444,873
R44 · FY2010 · CA
Camptothecin Analogs for Cancer Therapy$392,344
R44 · FY2011 · CA
DERIVATIVES OF DEMETHYLPENCLOMEDINE:ANTICANCER AGENTS$359,498
R44 · FY2001 · CA
ISOPHOSPHORAMIDE MUSTARD--A PHASE 1 STUDY$338,965
R44 · FY2001 · CA
DERIVATIVES OF DEMETHYLPENCLOMEDINE:ANTICANCER AGENTS$320,366
R44 · FY2003 · CA
Clinical Development of 4-Hydroperoxyifosfamide$294,271
R44 · FY2006 · CA
Clinical Development of 4-Hydroperoxyifosfamide$244,853
R44 · FY2007 · CA
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN: A Phase II Clinical Trial in Adolescents/Young Adults (AYA)with CNS Malignancies$240,368
R44 · FY2018 · CA
ISOPHOSPHORAMIDE MUSTARD--A PHASE 1 STUDY$225,894
R44 · FY2000 · CA
A-007: IMMUNE MODULATION OF HPV - CERVICAL CANCER$191,517
R43 · FY2001 · CA
Clinical Development of 4-Hydroperoxyifosfamide$185,641
R43 · FY2002 · CA
Camptothecin Analogs for Cancer Therapy$158,895
R43 · FY2007 · CA
A Phase I Clinical Trial: Binary Therapy with DM-CHOC-PEN and WBRT in Adults with Cancer Involving the CNS$143,294
R43 · FY2017 · CA
A Phase I Clinical Trial: Binary Therapy with DM-CHOC-PEN and WBRT in Adults with Cancer Involving the CNS$143,294
R43 · FY2018 · CA
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) Phase I Clinical Tr$140,983
R43 · FY2008 · CA